| Trial ID: | L1135 |
| Source ID: | NCT00261521
|
| Associated Drug: |
Epoetin Alfa
|
| Title: |
A Study of the Safety and Efficacy of Long-term Correction of Anemia With Epoetin Alfa in Early Hemodialysis Patients
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Kidney Failure, Chronic|Anemia
|
| Interventions: |
DRUG: epoetin alfa
|
| Outcome Measures: |
Primary: Percent change in left ventricular volume index (LVVI) at Week 96. | Secondary: Percent change at Week 96 in left ventricular mass index (LVMI), development of new heart failure, correlation between change in left ventricular indices and average maintenance hemoglobin, 6-minute walking test, and quality of life.
|
| Sponsor/Collaborators: |
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
596
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE|Primary Purpose: TREATMENT
|
| Start Date: |
2000-02
|
| Completion Date: |
2003-05
|
| Results First Posted: |
|
| Last Update Posted: |
2010-12-03
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT00261521
|
